Navigation Links
Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference

VANCOUVER, British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM), announced today the publication of new preclinical data from additional confirmatory animal studies showing that Allon's product candidate AL-108 significantly reduces the accumulation of amyloid peptide and the hyperphosphorylation of tau protein in the brain, two pathological hallmarks of Alzheimer's.

Gordon McCauley, Allon's President and Chief Executive Officer, announced this publication to a conference in New York sponsored by investment bank Leerink Swann & Company entitled "A Mind is a Terrible Thing to Waste: Emerging Trends for Alzheimer's Disease." The invitation only event for institutional investors, venture capitalists and hedge fund managers who invest in the healthcare sector, highlights select companies developing Alzheimer's treatments.

"Our Alzheimer's program is based on this very compelling data showing that our compounds work on both of the classic hallmarks of Alzheimer's disease and the Phase II efficacy program is enrolling well," said McCauley. "We believe that we have implemented a sound and strategically balanced clinical plan for our compounds and we anticipate the results eagerly."

"Data published in The Journal of Molecular Neuroscience shows that AL-108 can modify disease progression in one of the most relevant models of Alzheimer's disease and our clinical development program is working to demonstrate this capability in human clinical trials," McCauley said.

McCauley said Allon is focused on developing drugs to treat processes underlying numerous neurodegenerative diseases and injury of the central nervous system. Drugs on the market today treat only the symptoms of these diseases and conditions.

Webcast and Conference location

Allon Therapeutics' presentation will take place on Tuesday, April 3, 2007 at 2:15pm Ea stern Daylight Time at the Le Parker Meridien, located at 119 West 56th Street (between 6th and 7th Avenues), New York. To view the webcast of the presentation, please use the link below. For 90 days following the conference the same link can be used to view the webcast, or alternatively you can visit www.allontherapeutics.com to access the presentation.

Live webcast link: http://www.wsw.com/webcast/leerink9/npc.to/

About Allon

Allon Therapeutics Inc. is a clinical-stage Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer's, cognitive impairment, stroke, traumatic brain injury, multiple sclerosis and neuropathy. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company(TM)) and based in Vancouver. For additional information please visit the company's website: www.allontherapeutics.com

Forward Looking Statements

There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Allon's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Allon's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking stateme nts. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact

Investor and Media contact:
Allon Therapeutics Inc.
Aaron Keay, Manager, Investor Relations, 604-742-2540
Cell: 604-323-6911
akeay@allontherapeutics.com


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
(Date:4/27/2016)... , April 27, 2016 At ... the launch of a Phase 2 clinical study of ... in patients undergoing cochlear implantation (CI) surgery. This large, ... in Germany and ... middle ear at the time of surgery. "Despite advances ...
(Date:4/26/2016)... , April 26, 2016 US ... forecast to expand 4.9 percent annually to $27.6 ... other healthcare facilities to decrease rates of healthcare-associated ... prevention supplies, equipment, and services.  Although declining, the ... significantly above targeted levels set by the CDC.  ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... ... on April 4th, 2016 questioned the use of the HyProCure sinus tarsi ... “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, when indicated, ...
(Date:4/29/2016)... , ... April 30, 2016 , ... Mercy College is ... The following programs will be expanding due to high demand: Master of Business ... expansion will begin this summer. , School of Business Graduate Program Chair ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic ... the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain ... mood optimization products to the store is just one more way Shamangelic Healing ...
(Date:4/29/2016)... Torrance, CA (PRWEB) , ... April 29, 2016 ... ... physician advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and ... Talk Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new study ... severe congenital diaphragmatic hernia have better survival rates if surgery is performed early. ... condition where the diaphragm fails to form completely, letting abdominal organs into the ...
Breaking Medicine News(10 mins):